Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729736 | 0.83 | MAP2K1 (0.39) | BRD4KDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL22729542 | 0.82 | BRD4 (0.50) | BRD4NR4A2MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL22729458 | 0.81 | BRD4 (0.49) | BRD4NR4A2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL22729532 | 0.78 | BRD4 (0.47) | BRD4NR4A2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL22729764 | 0.77 | BRD4 (0.46) | BRD4NR4A2MAPTSMN1; SMN2CYP2C9 | |
| SCHEMBL20604834 | 0.77 | NR4A2 (0.43) | BRD4NR4A2MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL23212251 | 0.77 | BRD4 (0.44) | BRD4NR4A2MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL22729479 | 0.76 | BRD4 (0.55) | BRD4NR4A2MAPTKDM4EALDH1A1 | |
| SCHEMBL2710900 | 0.71 | BRD4 (0.51) | BRD4NR4A2MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL15539798 | 0.71 | BRD4 (0.44) | BRD4NR4A2MAPTSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | BRD4 1170/4885NR4A2 4236/4885MAPT 356/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | BRD4 1201/4885NR4A2 4290/4885MAPT 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.